Resverlogix Board Update - WDRB 41 Louisville News

Resverlogix Board Update

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Resverlogix Corp.

TSX Exchange Symbol: RVX

CALGARY, Feb. 11, 2014 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) announced today that Arthur Higgins will be stepping down from the Board of Directors after fulfilling his commitment in helping Resverlogix spin out Zenith Epigenetics. Resverlogix's management and Board of Directors would like to thank Arthur for his commitment and positive input during this time.

About Resverlogix

Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and our IR App found on Apple products iTunes and Android users (Google Play).

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and WDRB. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.